The purpose of this research study is to see if ganetespib could be a safe and effective treatment for advanced breast cancer.
A new diagnosed subjects with HER2+ disease
Presence of active or untreated CNS metastases
Bone as the only site of metastatic disease from breast cancer
Participants will be randomized to two groups. Group A includes HER2+ breast cancer participants and Group B includes triple negative breast cancer participants. Both groups will receive Ganetespib monotherapy. Participants will have medical exams, blood draws, PET/CT, MRI and other scans necessary for this study.